How Much Tricuspid Regurgitation Reduction Is Enough? Residual TR and Long-Term Outcomes After T-TEER in the Randomized TRI-FR Extension

31 August 2026 (15:00 - 15:15)

Organised by:

Video

Sign in for access options

About the speaker

Professor Erwan Donal

Hospital Pontchaillou of Rennes, Rennes (France)

3 More presentations in this session

Presentation thumbnail

Primary Results of the VHD-W (Valvular Heart Disease in Women) Study

Doctor J. Grapsa (Boston, US)

Presentation thumbnail

Medium-term outcomes following contemporary transcatheter aortic valve implantation in England: insights from national registry linkage

Professor R. Kharbanda (Oxford, GB)

Presentation thumbnail

Isolated Tricuspid Valve Replacement at 20-Year Follow-up. Insight from the largest multicenter international registry. DURABLE Tricuspid

Doctor E. Zancanaro (Mainz, DE)

Access the full session

Session thumbnail

Valvular heart disease: lessons from real-world practice

The Event

Event poster

ESC Congress 2026

31 August 2026 15:00 CET

You may be interested in

Congress Presentation

Residual tricuspid regurgitation after transcatheter tricuspid valve edge-to-edge repair: the EuroTR Registry

1 September 2024

Congress Presentation

Early health-status improvement after transcatheter tricuspid edge-to-edge repair predicts long-term reduction in heart-failure hospitalizations: insights from theTRI-FR randomized trial

30 August 2026

Congress Presentation

T-TEER - The level of evidence elevating the benefits of repair

28 August 2026

Congress Presentation

Transcatheter tricuspid valve implantation

28 August 2026

ESC 365 is supported by

novartis

Explore sponsored resources

novo-nordisk

Explore sponsored resources

ESC 365 is supported by

novartis

Explore sponsored resources

novo-nordisk

Explore sponsored resources